Advanced Representatives Talk about Experience
Release time:
2023-02-22
: At the commendation meeting of Jianfeng Pharmaceutical held on March 19 , , Cao Jiankai, the advanced representative of the group and the production department of the pharmaceutical company, Wu Weisheng, the representative of the advanced collective and the general manager of the pharmaceutical company, Zhang Sihan, the representative of the outstanding scientific and technological workers, the product development department, Fan Yongmei, the representative of the outstanding marketing staff and the sales department, took the stage to share their work experience and experience. This issue of "Peak News" specially excerpts some of the main contents of the speech for colleagues to share and learn.
Seize OpportunityTap Potential and Increase Efficiency Work Together to Promote Development
■ Advanced Collective Representative Jinhua Pharmaceutical Company2022
was a very unusual year. Faced with the severe epidemic prevention and control situation, pharmaceutical companies overcame the impact of epidemic control drug sales restrictions and traffic control and exceeded the responsibility system target.
Looking back on one year's work, there are mainly the following four highlights:
Seize the policy opportunity, and the Chinese Medicine Department has achieved substantial growth in sales and profits.
2022At the beginning of the year, Jinhua City implemented a new medical insurance payment policy for Chinese herbal pieces. Hospitals did not pay more attention to brand and quality in the purchase of Chinese herbal pieces. The Department of Traditional Chinese Medicine took the initiative to attack and follow up in time, actively adopted the hospital's demands for Chinese herbal pieces under the new regulations, and carried out targeted procurement and distribution of Chinese herbal pieces in accordance with the requirements of the hospital. While fully meeting the needs of the hospital, it achieved a substantial increase in sales in key hospitals. The pharmaceutical company became one of the two suppliers of Jinhua Hospital of Traditional Chinese Medicine. Becoming the main distributor of Yongkang Hospital of Traditional Chinese Medicine, the sales revenue of the Chinese Medicine Department increased 65.43 year on year . The pharmaceutical company also formed an alliance with Jinhua traditional Chinese Medicine Hospital to participate in the activity of "thousands of regiments, thousands of villages, jointly building common prosperity, and helping villages" organized by the Agricultural Office of Jinhua Municipal CPC Committee to help Shanfeng Village, Majian Town, Lanxi City; signed an agreement with the Education Foundation of Zhejiang University of traditional Chinese Medicine to continuously strengthen the cooperative relationship with Jinhua traditional Chinese Medicine Hospital, which is an affiliated hospital of Zhejiang University of traditional Chinese Medicine. The steady growth of
hemp essence drugs has consolidated the leading position of hemp essence drugs in Jinhua region. At the beginning of
, the pharmaceutical company strengthened the cooperation between Jinhua Charity Federation and Jinhua Central Hospital to realize exclusive distribution of special drugs of Jinyi Group. The sales of hemp essence drugs increased by more than 20% and throughout the year.
Western medicine department to find ways to tap the potential to increase efficiency, sales for the first time in recent years to achieve positive growth.
Hospital plate, the salesman strengthened the communication between medical institutions and suppliers, improved the quality of service, and stabilized the basic plate. At the same time, by expanding the sales of new hemp essence drugs and other varieties to make up for the loss of centralized varieties, after efforts, sales increased by more than 44,295 million yuan year on year. 12 After the optimization of the epidemic prevention and control policy in July, the explosive growth of the four major categories of drugs, the annual sales of the third terminal sector increased year-on-year 1650 million yuan. The grass-roots hospital sector has achieved good growth in Lanxi and Wucheng districts by understanding market trends, strengthening customer visits, improving service quality, and overcoming unfavorable factors such as the reduction of distribution varieties and the impact of epidemics. In January, it regained the distribution right of Yiwu market and gradually resumed its business in some markets. The annual sales volume increased by more than 460 million yuan year on year.
The whole company is united, united, and united, which is a sufficient guarantee to overcome the epidemic and exceed the goal of accountability.Jinhua
"4.15 " During the epidemic, in addition to strictly controlling the entry and exit of employees and outsiders, our company also required some employees living in controlled risk areas to stay in the company to avoid key positions being controlled and affecting the company's daily operations. This has also been understood and supported by relevant personnel, thus staying at the company at ease. In the end, our company has been operating normally during the outbreak. After the outbreak of the "4.15 " Jinhua epidemic, the company, as the Jinhua municipal government's epidemic prevention and control material reserve unit, cadres took the lead, organized personnel, supported the warehouse, received, distributed and transported all kinds of epidemic prevention and control materials, in the inventory of warehouse assets to generate income rent, but also contributed to the prevention and control of the epidemic in Jinhua City. The large volume of sales of Chinese medicine tablets and the explosive growth in sales of related drugs after the optimization of epidemic control measures have increased the workload of the warehouse. When the warehouse is understaffed, cadres take the lead. Salesmen, general manager office personnel, buyers and other personnel who can be vacated are all porters and shippers. They work overtime together with the warehouse keeper to ensure that the goods arriving on the same day are put into storage on the same day, the sales orders on the same day are out of storage on the same day, and it is common to work overtime until after in the evening at the beginning of each week or when the business volume.
Honor belongs to the past, we start again. In the new year, we have the opportunity to liberalize the control of the epidemic and fully resume normal operations, as well as the risk of a sharp rise in the purchase price of Chinese medicine tablets, fierce competition in the market for refined hemp drugs, and the loss of price cuts for key varieties of drug collection."Although the road is far, the journey will come. Although things are difficult, they will be done", accumulating steps and even thousands of miles. I believe that as long as we keep our feet on the ground, work hard, under the correct leadership and full support of the group company and the pharmaceutical company, and with the joint efforts of all employees, the 70-year-old pharmaceutical company will still be rejuvenated.
Find the right position
Keep your feet on the ground Improve yourself through learning
■ It has been seven years since Cao Jiankai
, the group's advanced representative, joined the peak family. Here I would like to share with you some experiences and thoughts in these years of work.
My first job in the company was a workshop equipment manager. At that time, I was unfamiliar with the equipment and its principles in the workshop. During the inspection and maintenance, although some of them had been learned in textbooks, I found that I could not start in actual operation. Fortunately, with the help of the teachers, I could gradually get started. Reading thousands of books is not as good as traveling thousands of miles, and reading books ten times is not as good as doing it once, which is my real feeling in the early days of my employment.
Company is preparing to build a new project in Anhui. At the time of employing people, the leader came to me. I think this is a good opportunity to learn. I thought my parents would disagree, but after a moment of silence, their words reassured me,
"Go if you have a chance! Since the company has chosen to believe you, you can do it well". So ignorant I embarked on a new journey to work in Anhui.
just arrived in Xinbeika, the strange atmosphere, strange environment, and work that I have never been in contact with, it is inevitable that I am not used to it at first, and even a little resistant, but I still stick to it. To adapt to the new job as soon as possible, we must improve our ability. During the preparation of the project, the drawings and materials of the design institute were my daily food, and the working platform gradually given by the leaders. With my previous work experience, I gradually adapted to the new job. Starting from the study of small technological transformation projects one by one, and finally being responsible for completing the installation of a workshop project independently. The experience along the way reminds me of our building's motto-"work is practice". I have a deep understanding of this. As young people, sometimes when facing different working environments and problems, we must learn to practice ourselves, actively adapt to the environment, find our own position, keep our feet on the ground, and improve ourselves through learning. The new generation of us should also have a heart of gratitude. The company has trained us, and we should contribute to the development of the company. We cannot identify ourselves as "workers", because I think the definition of "workers" refers to a group of people who work mechanically and have no thoughts. We should learn to think, think about how to make our work fast and efficient, and how to make our work bring benefits to the company.
I will continue to work hard to improve my working ability and live up to everyone's expectations of me. Keep in mind the mission of the company, with a more enthusiastic attitude and full spirit, to contribute to our"Centennial Peak.
More information
Two Cement Enterprises Prosperous Production and Sales in May
With the gradual easing of the new crown epidemic, all over the project has started, Hubei, Yunnan two provinces cement market continued to improve, Daye peak cement company, Yunnan peak cement company two enterprises have recently shown a good momentum of production and sales. In May, the sales volume of Yunnan Jianfeng cement continued to rise. As of the time of publication, the average daily shipment volume reached more than 7400 tons, and the highest daily shipment volume reached more than 8700 tons, and the production capacity was fully released. Over the past few days, Yunnan Peak Packaging System has made great efforts to overcome the impact of narrow distribution sites and many cement varieties to ensure the completion of delivery tasks with good quality and quantity every day. In order to further balance production and sales and create conditions for the homogenization of cement delivered from the factory, Yunnan peak packaging system puts forward work requirements for relevant posts, emphasizes equipment inspection and process inspection during production, strictly implements safety operation procedures, and maintains safe and efficient operation of the system. Due to the impact of the new crown epidemic, Hubei cement market started late, Wuhan market is the hardest hit area, the current project construction is still not fully started, the volume pressure is greater. For this reason, daye peak departments cooperate closely, increase market development efforts, develop new mixing stations, focus on increasing the bulk share of Xianning, Huanggang and Wuhan markets, seize the opportunity of fine weather, and achieve the goal of rapid output. Internally, on the basis of equipment technical renovation and production capacity improvement, the delivery is effectively guaranteed, and the daily delivery capacity can basically be maintained at 10,000 tons. In May, Daye Peak sold more than 300000 tons of cement, an increase of 20% over the same period last year, with an average daily sales volume of more than 9900 tons, the highest in the current period since Daye Peak was put into production.
2020
07-31
The company's "safe production month" activities are about to start
June 2020 is the 19th national "safe production month", the theme of the activity is "eliminating hidden dangers of accidents and building a strong line of defense". A few days ago, the group company issued a notice to arrange the activities related to the organization of "safe production month" and put forward requirements. According to the group's "safe production month" activity plan, different key thematic activities will be held in the four weeks of June. The first week is the "Publicity and Safety Education Week", which focuses on the use of WeChat groups, electronic screens, publicity boards, banners, slogans and other forms for safety publicity, and organizes the study of national safety regulations, company safety system specifications and accident-free factory creation standards, Organize to watch safety warning education films, learn accident cases, etc., and improve employees' safety awareness by creating a safety atmosphere and organizing learning activities. The focus of the activities in the second week is "looking for potential sources of danger around you". Each unit takes departments and teams as units to investigate and analyze the potential risk factors in the process of daily production, maintenance and operation, find out the hazard sources that have not been included in the scope of risk point control, and report to the safety management department of the unit to form a risk assessment report, put forward solutions or suggestions, and supervise the implementation of rectification and timely eliminate potential safety hazards. The third week is the "on-site safety innovation achievements exhibition week", which focuses on the achievements of each unit in on-site safety management and on-site safety facilities in the past year, which are displayed in the form of pictures and texts through beautiful articles and wechat, so as to learn from each other and promote common progress. The fourth week is the "safety training and drill week", and the group company organizes the standardization of safety production and the elimination of hidden dangers.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-30
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-22
On April 24, Jiang Xiaomeng, chairman of the group company, presided over the 14th meeting of the 10th board of directors of the company, and deliberated and passed 14 related reports and motions such as the 2019 annual board of directors report, the 2019 general manager business report and the 2019 annual report. The general manager's report pointed out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023) and the new three-year business plan (2019-2021) for each business sector. the management team has carried out various operation and management work in an orderly manner around the general policy of "innovation and reform, integration and promotion, scientific layout and steady development", and has better completed the business objectives set by the board of directors at the beginning of the year. In the whole year, the company achieved a total operating income of 3.548 billion billion yuan, an increase of 5.51 percent over the same period last year; net profit attributable to shareholders was 0.725 billion billion yuan, with earnings per share reaching 2.11 billion yuan, an increase of 23.14 percent over the same period last year, a record high; total assets at the end of the year were 5.475 billion billion yuan, an increase of 11.71 percent over the same period last year; and net assets attributable to shareholders were 3.789 billion billion yuan, an increase of 19.81 percent. During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, the overall operation of the cement industry in 2019 is stable, and the industry benefits are further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons of clinker.
2020
07-31